Login to Your Account

ThromboGenics Sets January Launch as FDA Approves Jetrea

By Cormac Sheridan
Staff Writer

Wednesday, October 24, 2012
In an eagerly awaited milestone for the company – and for Belgian biotech – the FDA recently approved ThromboGenics NV's biologic drug Jetrea (ocriplasmin) for treating symptomatic vitreomacular adhesion (VMA).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription